Kidney injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Preclinical Biomarker Qualification Studies
A Panel of Urinary Biomarkers to Monitor Reversibility of Renal Injury and a Serum Marker with Improved Potential to Assess Renal Function
October 5, 2010 Renal Biomarker Qualification Submission: A Dialog Between the FDA-EMEA and Predictive Safety Testing Consortium
October 5, 2010 Urinary Clusterin, Cystatin C, [beta]2-Microglobulin and Total Protein as Markers to Detect Drug-Induced Kidney Injury
C-Path is No. 7 in Reader’s Digest List of 18 Big Ideas to Fix Healthcare Now The November 2008 issue of Reader’s Digest lists 18 big ideas to fix healthcare now and the Critical Path Insitute is listed
FDA & EMEA to Consider Additional Test Results When Assessing New Drug Safety In the first use of a framework allowing submission of a single application to the two agencies, the Food and Drug Administration
C-Path Leads Novel Transatlantic Drug Safety Effort Companies receive go ahead from FDA and EMEA to use new improved tests when assessing safety of new drugs.
